Literature DB >> 18691028

Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates.

Zuhu Huang1, Arthur Chou, Jonathan Tanguay, Siyuan Shen, Innocent Mboudjeka, Te-Hui Chou, Shan Lu, Shixia Wang.   

Abstract

A good understanding about the structure and function of the envelope glycoprotein (Env) from primary human immunodeficiency virus-1 (HIV-1) isolates is important in facilitating the development of effective neutralizing antibody responses as a component of an effective HIV-1 vaccine. In the current study, the antigenicity of a panel of diverse HIV-1 primary Env from different clades of HIV-1 Group M was analyzed using rabbit sera produced by either 3- or 9-valent gp120 DNA vaccine formulations. Both the 3- and 9-valent gp120 DNA vaccine formulations elicited HIV-1 gp120-specific antibodies in immunized rabbits. However, we observed two levels of primary envelope antigenicity to the same set of rabbit immune sera and that the level of glycosylation, particularly in the V1 loop, may contribute to such diversity. Bioinformatics analysis on the distribution and average number of the N-linked glycosylation sites in all variable regions (V1-V5) was conducted. A linear plot demonstrated that the average number of potential N-glycosylation sites in the V1 and V4 loops correlates to the size of the loop. These data provide further evidence on the complexity of primary HIV-1 Env antigens and offers new insight into the mechanisms that HIV-1 uses to escape protective immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691028     DOI: 10.2174/157016208785132518

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  5 in total

Review 1.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

Review 2.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

3.  The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.

Authors:  Fatima Nawaz; Claudia Cicala; Donald Van Ryk; Katharine E Block; Katija Jelicic; Jonathan P McNally; Olajumoke Ogundare; Massimiliano Pascuccio; Nikita Patel; Danlan Wei; Anthony S Fauci; James Arthos
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

4.  HIV-1 envelope accessible surface and polarity: clade, blood, and brain.

Authors:  Gopichandran Sowmya; Gunasagaran Shamini; Sathyanarayanan Anita; Meena Sakharkar; Venkat Mathura; Hector Rodriguez; Andrew J Levine; Elyse Singer; Deborah Commins; Charurut Somboonwit; John T Sinnott; Harcharan S Sidhu; Ganapathy Rajaseger; Peter Natesan Pushparaj; Pandajarasamme Kangueane; Paul Shapshak
Journal:  Bioinformation       Date:  2011-03-22

5.  Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines.

Authors:  Shixia Wang; Te-Hui Chou; Anthony Hackett; Veronica Efros; Yan Wang; Dong Han; Aaron Wallace; Yuxin Chen; Guangnan Hu; Shuying Liu; Paul Clapham; James Arthos; David Montefiori; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.